Trial Profile
Anti-PD-1 Antibody SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma:an Open-label Phase II Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Mar 2021
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Decitabine (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 05 Mar 2021 Results (n=51) assessing evaluation of putative biomarkers of response to decitabine-plus-camrelizumab in relapsed/refractory cHL, published in the Clinical Cancer Research
- 30 Apr 2019 Results (n=86) published in the Journal of Clinical Oncology
- 28 Mar 2019 Planned End Date changed from 21 Mar 2020 to 21 Mar 2025.